Shikonin-induced apoptosis involves caspase-3 activity in a human bladder cancer cell line (T24)

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Apoptosis, or programmed cell death, is a critical cellular process and a significant therapeutic target in cancer treatment.
• Human bladder cancer, specifically transitional cell carcinoma, presents an ongoing challenge requiring novel therapeutic strategies.

Purpose of the Study:

• To evaluate the potential apoptotic effects of shikonin on human bladder cancer T24 cells in vitro.
• To investigate the mechanisms underlying shikonin-induced apoptosis, including cell cycle regulation and caspase activation.

Main Methods:

• In vitro evaluation of shikonin's effects on T24 cells, including apoptosis induction, cell viability, and morphological changes.
• Analysis of cell cycle regulation via cyclin-dependent kinase (CDK) and cyclin protein levels (p21, cyclin E, CDK2, CDK4).
• Assessment of caspase-3 and -9 activity using flow cytometry and reverse transcription-polymerase chain reaction (RT-PCR).

Main Results:

• Shikonin treatment led to significant G0/G1 cell cycle arrest and increased cell death in T24 cells compared to controls.
• Shikonin modulated cell cycle proteins by increasing p21 and decreasing cyclin E, CDK2, and CDK4 levels.
• Significant apoptosis induction was observed, confirmed by flow cytometry, with shikonin promoting caspase-3 activity, leading to downstream effects like CAD and PARP cleavage.

Conclusions:

• Shikonin effectively induces apoptosis in human bladder cancer T24 cells through caspase-3 activation.
• The observed caspase-3 activation and subsequent downstream events suggest a key role for this pathway in shikonin's anti-cancer effects.
• Shikonin demonstrates potential as a therapeutic agent for bladder transitional cell carcinoma due to its ability to induce apoptosis in cancer cells.